Enlivex Therapeutics Ltd. (ENLV) Institutional Ownership

Ownership Summary

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) currently has 21 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• Institutional ownership in Enlivex Therapeutics edged up to 5.2% in December 2025, compared to 3.8% in September 2025.
• The company experienced a 139.98% quarterly change in institutional shares held, alongside a decrease of 16.00% in total owners annually.
• A review of institutional activity for Enlivex Therapeutics shows 12 of 21 filers increasing their positions, while 2 reduced their stake, and 7 remained unchanged.
• The total number of shares held by institutions in Enlivex Therapeutics increased to 1.20Mn as of December 2025, a net change of up by 701.00K shares quarter on quarter, and down 2.21Mn shares year over year.
• RENAISSANCE TECHNOLOGIES LLC continues to be the largest institutional holder of Enlivex Therapeutics as of December 31, 2025, with a position of 313.63K shares, representing 1.36% of the company's outstanding stock.
• Among the most significant buyers of Enlivex Therapeutics during December 2025 were TWO SIGMA INVESTMENTS, LP (184.39K), RENAISSANCE TECHNOLOGIES LLC (156.34K), HRT FINANCIAL LP (135.20K), BANK OF AMERICA CORP /DE/ (84.97K), XTX Topco Ltd (61.80K).
• Leading sellers of Enlivex Therapeutics stock in December 2025 included CITADEL ADVISORS LLC (43.35K), Steward Partners Investment Advisory, LLC (2.00K).
• The top 10 institutional holders of Enlivex Therapeutics for the quarter ending December 2025 included RENAISSANCE TECHNOLOGIES LLC (313.63K), MORGAN STANLEY (200.63K), TWO SIGMA INVESTMENTS, LP (195.13K), HRT FINANCIAL LP (153.99K), BANK OF AMERICA CORP /DE/ (85.10K), JANE STREET GROUP, LLC (74.08K), XTX Topco Ltd (61.80K), UBS Group AG (34.99K), CITADEL ADVISORS LLC (25.59K), Prosperity Consulting Group, LLC (17.65K).